| Extramedullary multiple myeloma M Bhutani, DM Foureau, S Atrash, PM Voorhees, SZ Usmani Leukemia 34 (1), 1-20, 2020 | 182 | 2020 |
| Idecabtagene vicleucel for relapsed/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium DK Hansen, S Sidana, LC Peres, C Colin Leitzinger, L Shune, ... Journal of Clinical Oncology 41 (11), 2087-2097, 2023 | 151 | 2023 |
| Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib S Atrash, A Tullos, S Panozzo, M Bhutani, F Van Rhee, B Barlogie, ... Blood Cancer Journal 5 (1), e272-e272, 2015 | 115 | 2015 |
| Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance SZ Usmani, R Sexton, A Hoering, CJ Heuck, B Nair, S Waheed, ... Blood, The Journal of the American Society of Hematology 120 (8), 1597-1600, 2012 | 80 | 2012 |
| Patterns of central nervous system involvement in relapsed and refractory multiple myeloma A Abdallah, S Atrash, Z Shahid, M Jameel, M Grazziutti, S Apewokin, ... Clinical Lymphoma Myeloma and Leukemia 14 (3), 211-214, 2014 | 63 | 2014 |
| Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma R Khan, S Apewokin, M Grazziutti, S Yaccoby, J Epstein, F Van Rhee, ... Leukemia 29 (5), 1195-1201, 2015 | 53 | 2015 |
| Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy CJ Ferreri, MAT Hildebrandt, H Hashmi, LO Shune, JP McGuirk, ... Blood cancer journal 13 (1), 117, 2023 | 44 | 2023 |
| Results from the first phase 1 clinical study of the B-cell maturation antigen (BCMA) Nex T chimeric antigen receptor (CAR) T cell therapy CC-98633/BMS-986354 in patients (pts … LJ Costa, SK Kumar, S Atrash, M Liedtke, G Kaur, BA Derman, ... Blood 140 (Supplement 1), 1360-1362, 2022 | 36 | 2022 |
| CAR-T treatment for hematological malignancies S Atrash, K Bano, B Harrison, AO Abdallah Journal of Investigative Medicine 68 (5), 956-964, 2020 | 34 | 2020 |
| Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM). DK Hansen, KK Patel, LC Peres, MH Kocoglu, L Shune, G Simmons, ... Journal of Clinical Oncology 41 (16_suppl), 8012-8012, 2023 | 28 | 2023 |
| Response of metastatic mucosal melanoma to immunotherapy: it can get worse before it gets better S Atrash, I Makhoul, JS Mizell, L Hutchins, F Mahmoud Journal of Oncology Pharmacy Practice 23 (3), 215-219, 2017 | 27 | 2017 |
| Comparing outcomes of HIV versus non-HIV patients requiring mechanical ventilation V Pathak, ISH Rendon, S Atrash, VPR Gagadam, K Bhunia, ... Clinical Medicine & Research 10 (2), 57-64, 2012 | 25 | 2012 |
| Peripheral immunotype correlates with minimal residual disease status and is modulated by immunomodulatory drugs in multiple myeloma M Bhutani, D Foureau, Q Zhang, M Robinson, AS Wynn, NM Steuerwald, ... Biology of Blood and Marrow Transplantation 25 (3), 459-465, 2019 | 21 | 2019 |
| Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma S Atrash, M Robinson, D Slaughter, A Aneralla, T Brown, J Robinson, ... Blood cancer journal 8 (11), 107, 2018 | 20 | 2018 |
| Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study S Atrash, P Thompson-Leduc, MH Tai, S Kaila, K Gray, I Ghelerter, ... BMC cancer 21, 1-11, 2021 | 19 | 2021 |
| Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis S Atrash, EM Flahavan, T Xu, E Ma, S Karve, WJ Hong, G Jirau-Lucca, ... Blood cancer journal 12 (3), 46, 2022 | 18 | 2022 |
| Evaluation of montelukast for the prevention of infusion-related reactions with daratumumab DC Moore, JR Arnall, DL Thompson, AL Martin, J Robinson, A Ndiaye, ... Clinical Lymphoma Myeloma and Leukemia 20 (10), e777-e781, 2020 | 18 | 2020 |
| Safety and cost benefits of the rapid daratumumab infusion protocol IS Hamadeh, ES Reese, JR Arnall, E Kachur, AL Martin, M Schneider, ... Clinical Lymphoma Myeloma and Leukemia 20 (8), 526-532. e1, 2020 | 17 | 2020 |
| Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory multiple myeloma (RRMM) who have received a prior BCMA … CJ Ferreri, MAT Hildebrandt, H Hashmi, LO Shune, JP McGuirk, ... Blood 140 (Supplement 1), 1856-1858, 2022 | 15 | 2022 |
| Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience. DK Hansen, S Sidana, L Peres, L Shune, DW Sborov, H Hashmi, ... Journal of Clinical Oncology 40 (16_suppl), 8042-8042, 2022 | 15 | 2022 |
Saad Z. UsmaniChief of Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY在 mskcc.org 的电子邮件经过验证
